These data demonstrate that: (i) promotion between the first and second hits has a profound outcome on carcinogenesis, presumably by increasing the probability that a second hit will occur in a previously initiated cell; (ii) continued promotion after the second hit is required for full expression of malignancy; (iii) the classic initiation-promotion protocol can be extended to a multihit, multistage model.
Introduction
As suggested by Knudson (1) and Nowell (2) and now proven on a molecular basis, carcinogenesis involves the accumulation of multiple genetic lesions or hits in a single cell. Epidemiological studies on age-dependent cancer incidence have indicated that four to six genetic events or hits are necessary for tumor development (3) . Chromosomal and molecular analyses of human colorectal tumors have shown that on average four to five genetic alterations are required for colon carcinogenesis (4) . Numerous studies have indicated that a mutator phenotype or genetic instability is necessary for a single cell to accumulate these multiple discrete alterations (5) . Lifestyle factors such as diet, smoking, age of menarche and age of childbirth all greatly influence the carcinogenesis process in humans and many of these factors are thought to function at the promotion level. Therefore, while effecting the clonal expansion of initiated cells, tumor promotion may also be influencing later stages of carcinogenesis.
Numerous models exist to study carcinogenesis and one of the better characterized models is the mouse skin tumor promotion model. In this model, a single sub-threshold dose of a carcinogen such as 7,12-dimethylbenz [a] anthracene (D) is administered followed by the repetitive application of a tumor promoter such as 12-O-tetradecanoylphorbol-13-acetate (T). Benign squamous papillomas generally develop within 10 weeks and virtually all of these papillomas contain Ha-ras mutations (6) . A small percentage of these papillomas eventually progress to malignant squamous cell carcinomas (SCC). The progression of papillomas to SCC has been characterized phenotypically by inappropriate expression of certain membrane receptor/adhesion molecules (7, 8) , keratins (9) (10) (11) (12) , growth factors (13) (14) (15) and cyclins/cyclin-dependent kinases (16, 17) and genotypically with respect to alterations in p53 and further alterations in Ha-ras (18) (19) (20) (21) (22) .
Different approaches have been taken to expand this initiation/promotion model to a multihit model of carcinogenesis in an effort to better understand the factors which influence malignant conversion. For example, fractionating a single dose of 51.2 µg D into 50 treatments of 1 µg D on mouse skin increases the papilloma yield~5-fold and, more importantly, increases the number of SCCs 40-fold (23) and D-initiated papillomas repeatedly treated with additional mutagenic agents such as N-methyl-NЈ-nitro-N-nitroguanidine (MNNG) and urethane have a higher incidence of malignant conversion over papillomas treated with T only (24) . Collectively these experiments indicate that the later stages of carcinogenesis are influenced by further genetic alterations and that repetitive exposure to mutagenic agents such as D and MNNG affects the accumulation of further genetic alterations. While tumor promoters are thought to have little influence on the later stages of carcinogenesis, it has been suggested that promotion between genetic hits could also influence the rate and frequency of malignant conversion by increasing the target population of the genetically altered cells for the next genetic hit (25, 26) . In addition, cells with additional genetic damage may be further selected for by the promoter. With regard to hepatocarcinogenesis, Pitot and Dragen utilized an initiation-promotionprogression-promotion model and demonstrated how, after 70% partial heptectomy, the administration of ethylnitrosourea to diethylnitrosoamine-initiated/phenobarbital-promoted liver profoundly increases the incidence of hepatocellular carcinoma (27) . Indeed, a multihit/promotion process may occur in human populations and, therefore, experimental models to investigate how promotion between genetic hits influences carcinogenesis would be very useful.
In order to determine if clonal expansion between genetic hits could influence the rate and/or frequency of malignant conversion, we employed a D two-hit treatment protocol where D-initiated mice received either T or acetone (A) vehicle promotion for 6 weeks before the second hit of D was applied. By clonally expanding D-initiated cells for 6 weeks of T promotion we have greatly increased the probability of a second hit of D occurring in a cell with pre-existing D-induced alterations. Using this two-hit approach we have demonstrated that tumor promotion between two genetic hits produces synergistic tumor responses, a decrease in malignancy latency and increases the frequency of malignant conversion. Tumor harvesting FVB/N mice received a 100 mg/kg BrdU i.p. injection 1 h prior to killing. Skin tumors were harvested and portions from each tumor were fixed in acetone at 4°C for 24 h, processed through graded alcohols and xylenes and paraffin embedded for histopathological evaluation and immunohistochemistry. The remaining tumor portions were flash frozen in liquid nitrogen for molecular analysis. Acetone-fixed tumor sections were stained with hematoxylin and eosin and histopathologically evaluated to be either a papilloma, SCC or fibrosarcoma (28) . Immunohistochemistry Acetone-fixed FVB/N mouse skin tumor sections were deparaffinized in xylene and rehydrated through graded alcohols and Automation Buffer (Biomedia Corp., Foster City, CA). 
Materials and methods

Materials
Cornifin-α, keratin K8 and keratin K13
Endogenous peroxidases were quenched by a 3% H 2 O 2 incubation for 10 min. Following a 30 min block in 10% normal goat serum, tissue sections were incubated with either rabbit polyclonal SQ37A cornifin-α/SPRR1 (29) (1:10 000; courtesy of Anton M.Jetten), rabbit polyclonal keratin K13 (10) (1:500; courtesy of Claudio J.Conti) or rat monoclonal keratin K8 (TROMA 1; courtesy of Helene Baribault) antisera overnight at 4°C in a humidified chamber.
Bromodeoxyuridine
Prior to 3% endogenous peroxidase block, tissue sections were placed in Antigen Retrieval Solution (Biogenex) and microwaved on high for 5 min. Following a 30 min block in 10% normal goat serum tissue sections were incubated with mouse BrdU antisera (1:25; Becton-Dickinson, San Jose, CA) for 1 h at room temperature in a humidified chamber.
For all antibodies, detection was carried out using biotin-linked streptavidinperoxidase (Biogenex) with diaminobenzidine as the chromagen (DAB Substrate Kit; Biogenex). Light counterstaining was performed with Harrismodified hematoxylin. Positive controls included FVB/N mouse vaginal epithelium for keratin K13 (9), FVB/N mouse small intestine for keratin K8 (30) and D-initiated/T-promoted CD-1 squamous cell carcinoma for cornifin-α/SPRR1 (29), and A-treated mouse epidermis served as a negative control for all antibodies. Papilloma sections were also stained with biotinylated secondary IgG antibodies followed by biotin-linked streptavidin-peroxidase detection without using primary antibodies to control for non-specific binding.
Ha-ras selective UV radiation fractionation (SURF)-PCR-single-strand conformation polymorphism (SSCP) analysis
Acetone-fixed D/T/A/T and D/T/D/T tumor samples were processed for histopathological analysis with hematoxylin and eosin staining. SURF followed by PCR was used to specifically analyze keratinocyte populations in each tumor on stained microscope sections (31) . Using a marker pen, black dots were placed directly on the cells of interest and slides were placed on a UV transilluminator model TN-36 (UVP, San Gabriel, CA) tissue side down and irradiated for 3 h at 8000 µW/cm 2 . Each genomic DNA sample was derived from~100-200 cells. DNA samples isolated from normal epidermis and tumor tissues were amplified with primers specific for Ha-ras exon 1 (H 1A , GCAGCCGCTGTAGAAGCTATGA; H 1B , GTAGGCAGAGCTCACCTCT-ATA) and exon 2 (H 2A , GTTGTTTTGCAGGACTCCTA; H 2B , GCCAT-AGGTGGCTCACCTGTA). SSCP analysis was then performed for both exon 1 and exon 2 amplification products for each sample on a 9 or 7% nondenaturing polyacrylamide gel, respectively. In each PCR reaction for SSCP analysis, one primer was 32 P-end-labeled. Each mutation was confirmed at least twice by independent PCR reactions with the original DNA extract from XbaI digestion of the 207 bp PCR products of Ha-ras exon 2 from DNA containing an A182→T transversion produces a 122 bp fragment from the 3Ј-end. PCR products derived from 32 P-labeled H 2B primer were subjected to complete digestion with 5 U of XbaI at 37°C overnight, the products were analyzed on 6% denaturing and 7% non-denaturing polyacrylamide gels. The disappearance of the aberrant bands from the SSCP gel after XbaI digestion demonstrated complete digestion of the PCR products from the mutant allele. The presence of the 122 or the 207 bp bands on an autoradiogram after complete XbaI digestion indicates the existence of the mutant or the wild-type allele, respectively.
p53 PCR-SSCP analysis
Total RNA was isolated from D/T/A/T and D/T/D/T papillomas using the single-step method of RNA isolation by acid guanidinium thiocyanate/phenol/ chloroform extraction as described previously (32) . First strand cDNA synthesis was carried out using 1 µg total RNA and 0.5 µg oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer (Gibco BRL, Gaithersburg, MD). The reaction volume was 20 µl and contained 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 500 µM each dATP, dCTP, dGTP and dTTP and 200 U of M-MLV reverse transcriptase (Gibco BRL). Samples were incubated at 37°C for 1 h and 2 µl of each reaction was directly used for PCR. cDNA samples were subjected to PCR amplification of four 300-400 bp overlapping fragments which constitute the entire coding region of the p53 gene. The PCR reaction volume was 20 µl and contained 200 µM each dATP, dCTP, dGTP and dTTP, 1 µM primers (listed in Table I ), 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 and 2.5 U of Taq DNA polymerase. Samples underwent 30 amplification cycles (denaturation at 95°C for 30 s, annealing at 58°C for 30 s and extension at 72°C for 1 min). Aliquots of 2 µl of each PCR reaction were heated with 4 µl of sample buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue) at 95°C for 5 min and 1 µl of each sample mixture was loaded onto a 5% non-denaturing acrylamide gel. Electrophoresis was conducted at 20 W for 8 h with cooling by a fan. Gels were transferred to filter paper, dried at 80°C for 30 min and exposed to film for 24-48 h at room temperature. A 193 bp PCR fragment from Ha-ras exon 2 containing a codon 61 A→T mutation served as a positive control. 
Results
D/T/D/T mice exhibit greater than additive papilloma responses
D/T/D/T papillomas demonstrate an increase in suprabasal S phase cells and alterations in keratin 13 expression
D/T/D/T papillomas exhibit an increased rate of malignant conversion
In order to determine if in this two-hit model D also had the capacity to influence malignant conversion, all groups of mice were maintained under observation for 52 weeks ( Figure 4 and Table II All malignancies were subjected to histopathological analysis and were evaluated to be SCCs (28) . As shown in Table II , all groups with the exception of D/T/D/A and D/A/D/A exhibited a similar carcinoma/papilloma ratio. However, it should be noted that the propensity of D/T/D/T papillomas to undergo malignant conversion is underestimated because mice were killed 2-3 weeks after the onset of malignant tumor formation in order to harvest the tumors and conduct histological analysis. Regardless, it is evident that profound differences in malignancy latency and incidence exist between D/T/D/T and D/T/A/T mice ( Figure 4) .
The molecular target of the second D hit is not the remaining normal Ha-ras allele
Mutations in Ha-ras have been shown to be an early and frequent D-induced event in mouse skin carcinogenesis (6,33) ϩ, Ͻ25% papilloma; ϩϩ, 25-50% papilloma; ϩϩϩ, Ͼ50% papilloma. D/T/A/T and D/T/D/T papilloma tissue sections were probed with BrdU, keratin K8 or keratin K13 antibodies followed by horseradish peroxidase detection using diaminobenzidine as the chromagen.
and further genetic alterations favoring an increase in mutant Ha-ras gene dosage are also observed in the progression of D-initiated papillomas (18) (19) (20) , making mutant Ha-ras a highly influential event at various stages in mouse skin carcinogenesis.
One possibility in our model is that if the second hit of D occurs in a cell which already contains one mutant Ha-ras allele, then it could induce a mutation in the remaining normal Ha-ras allele, thereby rendering that cell with two mutant Haras alleles. This increase in mutant Ha-ras gene dosage could be responsible for the observed increases in papilloma multiplicity and malignant conversion. To determine if the normal Ha-ras allele was the target for the second D hit, SURF of D/T/D/T and D/A/D/T papilloma keratinocytes was employed to exclusively collect keratinocyte genomic DNA over DNA from infiltrative cells, stroma-derived cells or other contaminating cell sources (31) . Exons 1 and 2 of the Ha-ras gene were amplified and PCR products were subjected to SSCP analysis. All mutations found by SSCP were confirmed by a separate PCR reaction followed by XbaI restriction analysis, which selectively cuts PCR products containing a mutant Ha-ras (CTA) over a normal codon 61 (CAA). Amplified Ha-ras exon 2 products that were cut (mutant) or uncut (normal) were visualized on an autoradiogram after complete digestion with XbaI. As shown in Table IV (Table IV) . In addition, all D/T/D/T SCCs were also found to contain at least one normal Ha-ras allele (Table IV) . Although the p53 tumor suppressor gene has been shown not to be a molecular target for D (34), we conducted SSCP analysis of p53 in six D/T/D/T papillomas in order to exclude the unique possibility of p53 alterations being involved in our multihit/promotion model. Four overlapping PCR fragments were generated which together comprised the entire coding region of p53. No band shifts were observed in any of the six papillomas analyzed when compared with PCR fragments from A-treated epidermis (data not shown). SSCP results were While initiation in mouse skin is considered to be an infrequent event, recent studies in mouse epidermis have indicated that upwards of 0.1% of Ha-ras genes sustain a codon 61 mutation 24 h following topical carcinogen application (35) , which results in the generation of~6000 initiated basal keratinocytes (36) . At 9 days post-carcinogen application the levels of Ha-ras genes containing codon 61 mutations are undetectable (35) . In our model it is unlikely that additional hits from a second application of carcinogen would occur in the small population of pre-initiated cells in the absence of clonal expansion. However, the population of mutant Ha-rascontaining cells is increased by a factor of Ͼ10 4 during tumor promoter-driven clonal expansion of pre-neoplastic mouse skin (35) , which would greatly increase the target population of initiated cells to sustain a second hit of carcinogen. Therefore, in our model it is probable that two D hits occur in a single cell at some frequency in D/T/D/T mice. Perhaps the observed increases in papilloma yields in the D/T/D/T mice are due to increased survival of initiated keratinocytes resulting from a second D hit. We have previously demonstrated that D has the capacity to increase papilloma frequency and induce further genetic alterations in genetically initiated v-Ha-ras transgenic mouse skin (37) .
The carcinoma to papilloma ratio represents the percentage of total papillomas in a group of mice which undergo malignant conversion and as such can be used to delineate between benign tumorigenic responses versus carcinogenic responses. Experiments in FVB/N mice have shown that reducing the initiating dose of D reduces the total papilloma yield but does not change the total carcinoma yield, thereby increasing the carcinoma to papilloma ratio (38) . In our study there was a Greater than 90% of D-initiated mouse skin papillomas harbor an A182→T mutation in Ha-ras from a wide variety of tumor promoters (6, 39, 40) and exon 1 Ha-ras mutations are also highly selected for in mouse skin papillomas induced with other chemical initiators (41) , collectively indicating that Ha-ras activation is a highly favorable early event in skin tumorigenesis. Furthermore, both the pre-malignant progression and malignant progression stages in mouse skin multistage carcinogenesis are associated with a further imbalance in favor of mutant Ha-ras (18) (19) (20) 42) , making mutant Ha-ras a prominent theme throughout carcinogenesis. Hence, it is likely that if a second D hit occurred in a cell that already contained one mutant Ha-ras allele and this second hit induced a mutation in the remaining normal Ha-ras allele then this event would likely be highly selected for by T tumor promotion. However, all D/T/D/T papillomas and SCCs were found to contain at least one normal Ha-ras allele, indicating that if the remaining normal Ha-ras allele was hit then it was a non-propagating event in the presence of other non-Ha-ras D-induced events. Therefore, these changes induced by a second hit of D do not appear to involve an increase in mutant Ha-ras gene dosage. These results support our previous findings in v-Ha-ras transgenic mouse skin (37) .
Our data indicate that a second D hit occurring in a cell with a pre-existing D-induced Ha-ras mutation increases the population of initiated keratinocytes sensitive to T promotion and able to undergo malignant conversion and that tumor promotion can affect the later stages of carcinogenesis and that the mouse skin carcinogenesis model can be extended to a multihit/promotion model. These results may have important implications for human cancer risk assessment in demonstrating how tumor promoters not only promote out initiated cells but also increase the target cell population for re-occurring initiation exposures and promote the growth of this multihit population, thereby accelerating the rate of malignant conversion. Our results also indicate that non-Ha-ras D initiation target genes exist that can cooperate with mutant Ha-ras to increase the sensitivity of keratinocytes to promotion and malignant conversion.
